Sumatriptan Does Not Antagonize CGRP-Induced Symptoms in Healthy Volunteers

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in this randomized controlled trial publication.

Previous attempts to develop a pragmatic human model for testing new anti-migraine drugs, have failed.

Calcitonin gene-related peptide (CGRP) induces a mild headache in healthy volunteers and migraine-like headache in migraine patients.

The induced headache must respond to already established migraine treatment for validation.

Who Took Part

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

Thirty healthy volunteers were recruited to receive a 2-hour infusion of CGRP on 2 separate days.

The participants were pretreated with sumatriptan 1 day and with placebo the other day in a randomized double-blind cross-over fashion.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got CGRP (Calcitonin Gene-Related Peptide) and who got the comparison, which limits bias.

As a double-blind CGRP (Calcitonin Gene-Related Peptide) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the CGRP (Calcitonin Gene-Related Peptide) group a baseline to be compared against.

Each person switched between CGRP (Calcitonin Gene-Related Peptide) and the comparison at some point, usually with a gap in between.

During the infusion, a questionnaire about headache and side effects was administered.

Electrocardiography, heart rate, blood pressure, dermal blood flow, and diameter of peripheral arteries were monitored during the infusion.

Participants were carefully instructed to fill out a headache questionnaire at home until 12 hours after the infusion start.

Primary endpoints are difference between the sumatriptan day and the placebo day in area under the headache score curve (AUC) 0-2 hours after infusion start and in headache intensity 2 hours after infusion start.

The study was conducted at the Danish Headache Center in Glostrup, Denmark.

What Was Measured

PubMed files the paper under topics including Calcitonin Gene-Related Peptide, Healthy Volunteers, Migraine Disorders, Serotonin 5-HT1 Receptor Agonists, Sumatriptan and Vasodilator Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide).

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Headache), a journal based in United States.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, all human trials.